Search
Publications
Food Allergen Immunotherapy in Preschool Children: Do We Have the Evidence? [8-Aug-2023]
Loke P.; Vickery B.P.; Jones S.M.; Peters R.L.; Roberts G.; Koplin J.J.
Abstract
Standard care for the management of food allergies previously centered on allergen avoidance and the treatment of adverse reactions after allergen exposure. An increase in the development of immunotherapy treatments for food allergy has occurred
The importance of long-term follow-up of oral immunotherapy in food allergy. [2-Jul-2024]
Loke P.; Lloyd M.; Tang M.L.K.Safety of COVID-19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi-centre cohort study. [12-Aug-2022]
De Luca J.F.; Awad A.; Vogrin S.; Douglas A.P.; Lutjen A.; Gordon S.F.; Crawford N.W.; Barnes S. ; Trubiano J.A.Rotavirus gastroenteritis and asymptomatic infections in community child care centres [2012]
Buttery, JimClinical outcomes and characteristics of baked egg challenges in infants and children. [24-Dec-2021]
Pitkin S.; Stevenson-Smith E.; Tomlin M.; Taranto M.; Loke P.
Abstract
Background: Egg allergy is the most common food allergy in 12-monthold infants (8.9%). Previous studies have shown that about 70-80% of egg-allergic children can tolerate baked egg, which may improve quality of life through improved nutrition
Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study. [7-Aug-2024]
Loke P.; Wang X.; Lloyd M.; Ashley S.E.; Lozinsky A.C.; Gold M.; O'Sullivan M.D.; Quinn P.; Robinson M.; Galvin A.D.; Orsini F.; Tey D.; Su E.-L.; Axelrad C.; Pitkin S.; Metcalfe J.; Tang M.L.K.
Abstract
.Copyright © 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Long-term longitudinal quality of life outcomes following a phase 2a open-label study of probiotic and peanut oral immunotherapy (PPOIT). [9-Dec-2021]
Lloyd M.; Ashley S.; Hsiao K.; Pitkin S.; Dunn Galvin A.; Jayawardana K.; Lozinsky A.C.; Loke P.; Tang M.L.
Abstract
was evaluated at screening (T0), end-of- treatment (T2), and 12-months (T4) and 3-years (T5) post-treatment, using the Food Allergy Quality of Life Questionnaire -Parent Form (FAQLQ-PF) and Food Allergy Impact Measure (FAIM). FAQLQ-PF total score and sub
The prevalence of IGE-mediated food allergy and other allergic diseases in the first 10 years: the population-based, longitudinal healthnuts study. [11-Apr-2024]
Peters R.L.; Soriano V.X.; Allen K.J.; Tang M.L.K.; Perrett K.P.; Lowe A.J.; Wijesuriya R.; Parker K.M.; Loke P.; Dharmage S.C.; Koplin J.J.
Abstract
Background: There are limited longitudinal data on the population prevalence of allergic conditions during childhood, and few studies have incorporated the reference standard oral food challenge to confirm food allergy. Objective(s): To describe
Effect of venom immunotherapy and sting challenge on HRQoL measured by venom-allergy quality of life questionnaire (VQLQ) in Jack jumper ant allergic patients. [17-Sep-2024]
Spriggs K.; Leahy E.; Weibel N.; Barnes S.Interaction between baseline participant factors and treatment effects following peanut oral immunotherapy. [5-Jan-2024]
Lloyd M.; Loke P.; Ashley S.; Lozinsky A.C.; Orsini F.; O'Sullivan M.; Gold M.; Quinn P.; Metcalfe J.; Tang M.L.
Abstract
placebo-controlled food challenge, cumulative 4950mg peanut protein, at 8-weeks post-treatment) and HRQL (change in Food Allergy Quality of Life Questionnaire-Parent Form score). Interactions between baseline factors and treatment effects on remission
Discover
By type
- 4768 Publications
- 20 Author profiles